Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/18/26
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic CancerGlobeNewsWire • 09/14/26
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 09/11/26
Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.Business Insider • 09/05/26
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/04/26
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung CancerGlobeNewsWire • 09/02/26
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC ExpansionsSeeking Alpha • 08/31/26
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic CancerMarketBeat • 08/28/26
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales.The Motley Fool • 08/28/26
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy TranscriptSeeking Alpha • 08/27/26
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock SurgesBenzinga • 08/27/26
Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival ResultsBenzinga • 08/27/26
U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic CancerGlobeNewsWire • 08/26/26
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.Barrons • 08/26/26
The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosisWSJ • 08/26/26
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?The Motley Fool • 08/25/26
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger OpportunityThe Motley Fool • 08/24/26